AbbVie introduces new pipeline for investments
As a company, AbbVie is focused on creating these new therapies. Its late and early-stage pipelines are designed to encourage long-term sustainable performance; the early-stage pipeline is dedicated to resetting the standards of care for immunology, oncology and neuroscience, while the late-stage pipeline is meant to create over 20 new indications or medicines by the year 2020.
"Since becoming an independent company in 2013, AbbVie has developed a robust and diversified pipeline focused on diseases that have compelling medical needs," Richard Gonzalez, chairman and CEO of AbbVie, said. "AbbVie's R&D pipeline of more than 50 active clinical development programs has AbbVie poised to deliver a consistent stream of innovative new medicines for patients while driving long-term growth through 2020 and beyond."
AbbVie made this announcement at a research and development meeting that included the investment community. The company is emphasizing its newest pipelines and advances for further investments.
"AbbVie's late-stage pipeline has the potential to deliver more than 20 new medicines or indications by 2020, with the approval of seven new medicines or indications expected in 2016," Michael Severino, AbbVie's chief scientific officer, said. "These new medicines, combined with our early-stage clinical programs, have the potential to address medical need, elevate the standard of care and improve patient outcomes."
Organizations in this story
AbbVie 1 N Waukegan Rd Lake Bluff, IL - 60044